title: Evaluation of renal grafts in patients with lupus nephritis as cause of end-stage renal disease.
abstract: BACKGROUND
  Kidney transplantation is the best option in end-stage renal disease (ESRD). For many years patients affected with lupus nephritis have had poor graft results. However, this has been changing over recent years with the development of new immunosuppressive drugs and a better comprehension of the natural evolution of the entity.
  
  
  METHODS
  We studied 20 patients with lupus nephritis who received 22 kidney grafts: 15 women and five men (n = 11) who were treated with cyclosporine or with tacrolimus (n = 11). Secondary immunosuppression included mycophenolate match (MMF) (n = 13) or azathioprine (n = 9). We analyzed human leukocyte antigen, cold ischemia time, acute tubular necrosis, creatinine, cholesterol, triglycerides, glucose, blood pressure, acute rejection episodes, immunosuppression, infections, disease recurrences, as well as graft and patient survival.
  
  
  RESULTS
  After a mean cold ischemia time of 22 +/- 4 hours, nine patients displayed delayed graft function of an average duration 9 +/- 4 days. At 36 +/- 35 months nine grafts were lost: two due to acute rejection; five to chronic allograft nephropathy; and two to venous thrombosis. One patient died of hemorrhagic shock. There were five cytomegalovirus infections. Graft survival was dependent on the type of secondary immunosuppression, incidence of acute rejection episodes and occurrence of delayed graft function.
  
  
  CONCLUSIONS
  We found no clinical recurrence of lupus nephritis after transplantation and a low incidence of complications, although there was a trend toward thrombosis. The presence of delayed graft function, episodes of acute rejection, and receiving azathioprine instead of MMF as secondary immunosuppression were associated with poorer graft survival.
authors.affiliation: Servicio de Nefrologia, Hospital Juan Canalejo, A Coruña, Spain. ptivv@canalejo.org
authors.forename: P
authors.initials: P
authors.lastname: Villaverde Verdejo
authors.forename: C
authors.initials: C
authors.lastname: Fernández Rivera
authors.forename: A
authors.initials: A
authors.lastname: Alonso Hernández
authors.forename: R
authors.initials: R
authors.lastname: Garcia Naveiro
authors.forename: M
authors.initials: M
authors.lastname: Cao Vilariño
authors.forename: C
authors.initials: C
authors.lastname: Tresancos Fernández
authors.forename: F
authors.initials: F
authors.lastname: Valdés Cañedo
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D008180:Lupus Erythematosus, Systemic; D008181:Lupus Nephritis / Q000601:surgery*; D008297:Male; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D012086:Reoperation; D013927:Thrombosis / Q000453:epidemiology; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents